[20180118]IF10813_医疗产品创新与监管:收益与风险 .pdf

上传人:任我行 文档编号:26952 上传时间:2022-06-24 发布时间:2019-04-30 格式:PDF 页数:3 大小:390.16KB
下载 相关 举报
[20180118]IF10813_医疗产品创新与监管:收益与风险 .pdf_第1页
第1页 / 共3页
[20180118]IF10813_医疗产品创新与监管:收益与风险 .pdf_第2页
第2页 / 共3页
[20180118]IF10813_医疗产品创新与监管:收益与风险 .pdf_第3页
第3页 / 共3页
亲,该文档总共3页,全部预览完了,如果喜欢就下载吧!
资源描述

1、 https:/crsreports.congress.gov January 18, 2018Medical Product Innovation and Regulation: Benefits vs. Risks Prior to marketing in the United States, medical products are reviewed for safety and effectiveness by the Food and Drug Administration (FDA). Medical products regulated by FDA include presc

2、ription drugs, medical devices, and biologics. During the premarket review process, FDA balances the benefits that patients may receive from using the product against the harms or risks that some patients may experience. Brief History of Medical Product Regulation Congressional action to regulate me

3、dical products has often been in reaction to harm caused by an under regulated medical product. The Biologics Control Act of 1902 was the first attempt to regulate a pharmaceutical product at the national level. It was also the first premarket approval statute, in contrast to a retrospective postmar

4、ket product evaluation. The Biologics Control Act was passed in response to deaths, many in children, from tetanus contamination of smallpox vaccine and diphtheria antitoxin. The act focused on the manufacturing process and required that facilities be inspected before a federal license was issued to

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告